Gene-Editing Trial Reports Lasting Results Three Years On

Three years after a small group of patients received a one-time gene-editing treatment for a severe inherited blood disorder, the results are holding — and that durability may matter as much as the cure itself.

The disorder once meant a life of transfusions, hospital stays and shortened horizons. The treatment, which edits a patient’s own cells to switch on a dormant, healthy form of a protein, was always promising in the lab. The open question was whether a single intervention would last, or whether the body would slowly undo the fix.

The latest follow-up suggests it lasts. The treated patients remain free of the transfusions that once defined their lives. The edited cells have persisted and continue to do their job. For a field that has spent years promising cures and delivering hopeful early data, three years of stable results is a different order of evidence.

The caveats are real and familiar. The trial is small. The treatment is, for now, staggeringly expensive — a price that puts it out of reach for most of the patients who could benefit, many of whom live in the parts of the world where the disorder is most common. A cure that only the wealthy can afford is a scientific triumph and an ethical problem at once.

Still, the science has crossed a threshold. The question is no longer whether a precise genetic edit can cure an inherited disease. It is how to make that cure cheap enough, and accessible enough, to reach the people who need it most.